Prestige Consumer Healthcare (PBH) Set to Announce Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) will be posting its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Prestige Consumer Healthcare to post earnings of $1.09 per share for the quarter. Prestige Consumer Healthcare has set its FY25 guidance at $4.40-4.46 EPS and its FY 2025 guidance at 4.400-4.460 EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.86 by $0.04. The company had revenue of $267.10 million for the quarter, compared to analyst estimates of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The firm’s revenue was down 4.4% on a year-over-year basis. During the same period last year, the firm earned $1.06 earnings per share. On average, analysts expect Prestige Consumer Healthcare to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $73.79 on Tuesday. The company has a market capitalization of $3.66 billion, a price-to-earnings ratio of 18.04, a PEG ratio of 2.08 and a beta of 0.47. The company has a current ratio of 3.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.65. Prestige Consumer Healthcare has a 12 month low of $56.61 and a 12 month high of $75.80. The stock has a 50 day moving average of $72.19 and a 200 day moving average of $69.62.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PBH. DA Davidson boosted their price objective on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $94.20.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.